Aptus Pharma Limited IPO Details

SME

Aptus Pharma IPO opens for subscription on 23 Sep 2025 and closes on 25 Sep 2025. The IPO will be listed on BSE with the tentative listing date set for 30 Sep 2025.

Aptus Pharma IPO price band has been fixed at ₹65 – ₹70 per share.The face value is ₹10 per share with a lot size of 2000.

Aptus Pharma IPO total issue size comprises 18,60,000 shares (aggregating up to ₹13.02 Cr). This includes a fresh issue of 18,60,000 shares (aggregating up to ₹13.02 Cr). Pre-issue shareholding stands at 50,00,000, which will increase to 68,60,000 post-issue.

Aptus Pharma IPO carries a ₹4 (5.7%) GMP, reflecting investor sentiment.

Aptus Pharma IPO Lot Size : Individual Minimum is 2 lots (4,000 shares) amounting to ₹280,000. Individual Maximum is 2 lots (4,000 shares) amounting to ₹280,000. SHNI Minimum is 3 lots (6,000 shares) amounting to ₹420,000. SHNI Maximum is 7 lots (14,000 shares) amounting to ₹980,000. BHNI Minimum is 8 lots (16,000 shares) amounting to ₹1,120,000.

The Lead Managers for Aptus Pharma IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Interactive Financial Services Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Market-Hub Stock Broking. You can analyze their track record by checking the Market Maker Performance Summary report.

For detailed information, Refer to the Aptus Pharma Limited RHP.

Aptus Pharma IPO Details

Listing Price : ₹80.8 at a Premium of 15.43%
Open Date
23 Sep 2025
Close Date
25 Sep 2025
Listing Date
30 Sep 2025
Issue Price
₹65 - ₹70
Face Value
₹10 per share
Lot Size
2000
GMP
₹4 (5.7%)
Issue Type
IPO
Listing On
BSE
Type
Book Built Issue
Share holding pre issue
5000000
Share holding post issue
6860000
Total Issue Size
18,60,000 shares (aggregating up to ₹13.02 Cr)
Fresh Issue
18,60,000 shares (aggregating up to ₹13.02 Cr)
Offer for Sale
-

Aptus Pharma IPO Subscription

Aptus Pharma IPO Application Wise Breakup

Aptus Pharma IPO Dates

  • 23 Sep 2025
    Opening dateOPD
  • 25 Sep 2025
    Closing dateCOD
  • 26 Sep 2025
    Allotment Date BOA
  • 29 Sep 2025
    Initiation of RefundsIOR
  • 29 Sep 2025
    Credit of SharesCOS
  • 30 Sep 2025
    Listing dateLID

Aptus Pharma IPO Lot Size

ApplicationLotsSharesAmount
Individual Minimum24000₹280,000
Individual Maximum24000₹280,000
SHNI Minimum36000₹420,000
SHNI Maximum714000₹980,000
BHNI Minimum816000₹1,120,000

Aptus Pharma IPO Reservation

Promoter Holding

Pre Issue:100%
Post Issue:72.89%
Promoter Names:
Tejash Maheshchandra Hathi, Chatrabhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya, Milly Chetan Lalseta, Riddhish Natwarlal Tanna, Gaurang Rameshchandra Thakker, Kripaliben Mayank Thakker, Kunjal Piyushbhai Unadkat

Aptus Pharma IPO Valuations

ROE:44.50%
ROCE:45.66%
DEBT/EQUITY:1.49
RONW:44.50%
P/E Pre IPO:11.29
P/E Post IPO:15.49

Aptus Pharma Financial Information

Period Ended31 Mar 202531 Mar 202431 Mar 2023
Assets21.9210.036.22
Total Income24.6417.8813.90
Profit After Tax3.100.800.19
EBITDA4.761.490.57
Net Worth6.971.770.97
Reserves and Surplus1.971.470.67
Total Borrowing10.365.312.21
Amount in ₹ Crore

About Aptus Pharma IPO

Aptus Pharma manufactures and distributes a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.

Products:

  • Aptus Pharma: Focuses on acute therapies i.e, anti-infectives, pain management, etc.
  • Aptus CD care: Focused on chronic therapies
  • Aptus Wellcare: Offers wellness and nutraceutical products
  • Aptus Global: Export in overseas market

As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments.

Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel.

 

Strength Of Aptus Pharma IPO

1. Diversified Product Portfolio.

2. Robust and Responsive Distribution Network.

3. Strategic Manufacturing Partnerships.

4. Commitment to High-Quality Standards.

5. Competitive and Cost-Effective Pricing.

6. Skilled and Committed Human Resources.

7. Experienced and Visionary Management Team.

8. Customer Satisfaction and Retention.

Risk Of Aptus Pharma IPO

1. We do not have our own manufacturing facility for pharmaceutical products and we have to rely on third parties for contract manufacturing of the products sold by our Company.

2. We are required to obtain, renew or maintain certain material statutory and regulatory permits and approvals required to operate our business, and if we fail to do so in a timely manner or at all, we may be unable to operate our business and our results of operations may be adversely affected.

3. We derive a significant part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us or to terminate our contracts or purchase orders, our business, cash flows, financial condition and results of operations may be adversely affected.

4. If we are unable to protect our intellectual property rights, our business, results of operations and financial condition may be adversely affected. Further, if our products were found to be infringing on the intellectual property rights of a third-party, we could be required to cease selling the infringing products, causing us to lose future sales revenue from such products and face substantial liabilities for infringement of intellectual property rights.

5. Our Company may be exposed to product liability and other claims arising from defective medicines manufactured by third-party Contract Manufacturers, despite having manufacturing agreements in place, as indemnity terms are not pre-determined.

6. We are highly dependent on the medical practitioners including general physicians, paediatricians, gynaecologists, cardiologists, endocrinologists, neurologists, and others. Any disruption in such understanding may adversely impact our business operations.

7. Our business is working capital intensive. If we are unable to borrow to meet our working capital requirements, it may materially and adversely affect our business and results of operations.

8. We have had negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on our business and operations.

9. Our Company does not have intellectual property rights over its corporate logo. In absence of our Registered Logo or Trademark there are chances of getting damage to our business prospects, reputation and goodwill and misuse of our logo.

10. There have been certain delays in filing of GST, PF/ESIC returns of the company. Consequently, we may be subject to adverse regulatory actions and penalties for any past or future non-compliance and our business, financial condition and reputation may be adversely affected.

Objectives Aptus Pharma IPO

1. Capital Expenditure for Office Premises with furniture and Industrial Racks

2. Working Capital

3. General corporate purposes

Company Contact Details

Aptus Pharma Ltd.
Ashutosh Buildcon, Opp. Slok - 2,
Nr. Harikrupa Logistic Park,
Aslali, Ahmedabad, Daskroi,
Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/

Registrar Contact Details

Name: Bigshare Services Pvt Ltd
Phone: +91-22-62638200

Comments